136 related articles for article (PubMed ID: 8485621)
1. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: milacemide.
Semba J; Curzon G; Patsalos PN
Br J Pharmacol; 1993 Apr; 108(4):1117-24. PubMed ID: 8485621
[TBL] [Abstract][Full Text] [Related]
2. Simple and rapid micro-analytical procedures for the estimation of milacemide and its metabolite glycinamide in rat plasma and cerebrospinal fluid by high-performance liquid chromatography.
Semba J; Ratnaraj N; Patsalos PN
J Chromatogr; 1991 Apr; 565(1-2):357-62. PubMed ID: 1874879
[TBL] [Abstract][Full Text] [Related]
3. Formation of the neurotransmitter glycine from the anticonvulsant milacemide is mediated by brain monoamine oxidase B.
Janssens de Varebeke P; Cavalier R; David-Remacle M; Youdim MB
J Neurochem; 1988 Apr; 50(4):1011-6. PubMed ID: 3346666
[TBL] [Abstract][Full Text] [Related]
4. Milacemide effects on the temporal inter-relationship of amino acids and monoamine metabolites in rat cerebrospinal fluid.
Semba J; Patsalos PN
Eur J Pharmacol; 1993 Jan; 230(3):321-6. PubMed ID: 8440309
[TBL] [Abstract][Full Text] [Related]
5. A microdialysis study of glycinamide, glycine and other amino acid neurotransmitters in rat frontal cortex and hippocampus after the administration of milacemide, a glycine pro-drug.
Doheny MH; Nagaki S; Patsalos PN
Naunyn Schmiedebergs Arch Pharmacol; 1996 Jul; 354(2):157-63. PubMed ID: 8857592
[TBL] [Abstract][Full Text] [Related]
6. Milacemide, a glycine pro-drug, inhibits strychnine-allodynia without affecting normal nociception in the rat.
Khandwala H; Loomis CW
Pain; 1998 Jul; 77(1):87-95. PubMed ID: 9755023
[TBL] [Abstract][Full Text] [Related]
7. Is the oxidation of milacemide by monoamine oxidase a major factor in its anticonvulsant actions?
O'Brien EM; Tipton KF; Strolin Benedetti M; Bonsignori A; Marrari P; Dostert P
Biochem Pharmacol; 1991 Jun; 41(11):1731-7. PubMed ID: 2043162
[TBL] [Abstract][Full Text] [Related]
8. Does FAD-dependent polyamine oxidase contribute to the metabolism of milacemide?
Strolin Benedetti M; Cocchiara G; Colombo M; Dostert P
J Neural Transm Suppl; 1990; 32():351-6. PubMed ID: 2128509
[TBL] [Abstract][Full Text] [Related]
9. MAO activity, metabolism and anticonvulsant activity of milacemide in rats and mice.
Colombo M; Strolin Benedetti M; Bonsignori A; Cocchiara G; Roncucci R; Dostert P
J Neural Transm Suppl; 1990; 32():123-9. PubMed ID: 2089081
[TBL] [Abstract][Full Text] [Related]
10. Antiepileptic drug pharmacokinetics and neuropharmacokinetics in individual rats by repetitive withdrawal of blood and cerebrospinal fluid: phenytoin.
Lolin YI; Ratnaraj N; Hjelm M; Patsalos PN
Epilepsy Res; 1994 Oct; 19(2):99-110. PubMed ID: 7843173
[TBL] [Abstract][Full Text] [Related]
11. Microionophoretic study with milacemide, a glycine precursor, on mammalian central nervous system cells.
Godfraind JM
Br J Pharmacol; 1990 May; 100(1):119-25. PubMed ID: 2196964
[TBL] [Abstract][Full Text] [Related]
12. Effect of milacemide on extracellular and tissue concentrations of dopamine and 5-hydroxytryptamine in rat frontal cortex.
Semba J; Doheny M; Patsalos PN; Sarna G; Curzon G
Br J Pharmacol; 1992 Jan; 105(1):59-62. PubMed ID: 1596690
[TBL] [Abstract][Full Text] [Related]
13. Effects of the glycine prodrug milacemide (2-N-pentylaminoacetamide) on catecholamine secretion from isolated adrenal medulla chromaffin cells.
Yadid G; Zinder O; Youdim MB
Br J Pharmacol; 1991 Nov; 104(3):760-4. PubMed ID: 1797336
[TBL] [Abstract][Full Text] [Related]
14. Monoamine oxidase inhibitory properties of milacemide in rats.
Truong DD; Diamond B; Pezzoli G; Mena MA; Fahn S
Life Sci; 1989; 44(15):1059-66. PubMed ID: 2784529
[TBL] [Abstract][Full Text] [Related]
15. The novel neuropsychotropic agent milacemide is a specific enzyme-activated inhibitor of brain monoamine oxidase B.
Janssens de Varebeke P; Pauwels G; Buyse C; David-Remacle M; De Mey J; Roba J; Youdim MB
J Neurochem; 1989 Oct; 53(4):1109-16. PubMed ID: 2769256
[TBL] [Abstract][Full Text] [Related]
16. The pharmacokinetics of vigabatrin in rat blood and cerebrospinal fluid.
Tong X; Ratnaraj N; Patsalos PN
Seizure; 2007 Jan; 16(1):43-9. PubMed ID: 17118677
[TBL] [Abstract][Full Text] [Related]
17. The interactions of milacemide with monoamine oxidase.
O'Brien EM; Tipton KF; McCrodden JM; Youdim MB
Biochem Pharmacol; 1994 Feb; 47(4):617-23. PubMed ID: 8129740
[TBL] [Abstract][Full Text] [Related]
18. Species differences in the interactions of the anticonvulsant milacemide and some analogues with monoamine oxidase-B.
O'Brien EM; Dostert P; Tipton KF
Biochem Pharmacol; 1995 Jul; 50(3):317-24. PubMed ID: 7646533
[TBL] [Abstract][Full Text] [Related]
19. The pharmacokinetic inter-relationship of tiagabine in blood, cerebrospinal fluid and brain extracellular fluid (frontal cortex and hippocampus).
Wang X; Ratnaraj N; Patsalos PN
Seizure; 2004 Dec; 13(8):574-81. PubMed ID: 15519917
[TBL] [Abstract][Full Text] [Related]
20. Interactions of some analogues of the anticonvulsant milacemide with monoamine oxidase.
O'Brien EM; Dostert P; Pevarello P; Tipton KF
Biochem Pharmacol; 1994 Aug; 48(5):905-14. PubMed ID: 8093103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
